Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Obesity 1Neoplasms, Second Primary 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Healthy Adult Participants 1Dyslipidemias 1Carcinoma, Non-Small-Cell Lung 1Behavior, Addictive 1

Interventions

Paclitaxel 72Bevacizumab 63Carboplatin 57pembrolizumab 47olaparib 33Gemcitabine 29Specimen Handling 27Cyclophosphamide 27liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 20Taxes 20Nivolumab 19Topotecan 18fludarabine 17Biopsy 17Doxorubicin 15Immunoglobulin G 13Disulfides 13Fulvestrant 12Oxaliplatin 11Blood Specimen Collection 11durvalumab 10Ipilimumab 10Fluorouracil 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Bupropion × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡